<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448172</url>
  </required_header>
  <id_info>
    <org_study_id>C1171010</org_study_id>
    <nct_id>NCT03448172</nct_id>
  </id_info>
  <brief_title>Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects</brief_title>
  <official_title>A Phase 1, Open Label, Single-period, Non-randomized Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance, And Metabolism Of [14c]Pf-05221304 Administered Orally To Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to characterize the absorption, distribution, metabolism, and
      excretion (ADME) of a single oral dose of [14C]PF-05221304 in Healthy Adult Male Subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Anticipated">June 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Cumulative recovery of urinary, fecal, and total excretion of radioactivity over time expressed as percentage of total radioactive dose administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic profiling for PF-05221304 in plasma, urine, and feces</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Percent (%) of each radiolabeled drug-related material (parent and each metabolite) will be determined in plasma, urine and feces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radioactivity AUClast</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for radioactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PF-05221304 AUClast</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-05221304</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radioactivity AUCinf</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for radioactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PF-05221304 AUCinf</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for PF-05221304</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radioactivity Cmax</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax) for radioactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PF-05221304 Cmax</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax) for PF-05221304</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radioactivity Tmax</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration for radioactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PF-05221304 Tmax</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration for PF-05221304</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radioactivity t1/2</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Plasma Decay Half-Life (t1/2) for radioactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PF-05221304 t1/2</measure>
    <time_frame>0-96 hr</time_frame>
    <description>Plasma Decay Half-Life (t1/2) for PF-05221304</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing an adverse event</measure>
    <time_frame>Up to 28 days post dosing of IP on Day 1</time_frame>
    <description>Assessment by physical examinations, adverse event monitoring, clinical laboratory measurements, vital signs and ECG.
Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity. Treatment-emergent are events between dosing with study drug and up to 28 days after that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Investigational Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14C]PF-05221304</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]PF-05221304</intervention_name>
    <description>a single oral dose of [14C]PF-05221304 (50 mg/100 ÂµCi liquid formulation)</description>
    <arm_group_label>Investigational Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages of 18 and 45 years, inclusive.

          2. Body mass index (BMI) of &gt;= 17.5 and &lt;= 30.4 kg/m2

          3. Total body weight &gt; 50 kg (110 lb).

        Exclusion Criteria:

        1. Evidence or history of clinically significant hematological, renal, endocrine,
        pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, allergic
        disease or clinical findings.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Covance CRU</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1171010&amp;StudyName=A+Phase+1%2C+Open+Label%2C+Single-period%2C+Non-randomized+Study+To+Evaluate+The+Pharmacokinetics%2C+Excretion%2C+Mass+Balance%2C+And+Metabolism+Of+%5B14c%5Dpf-05221304+Administered+Orally+To+Healthy+Adult+Male+Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

